What is OncoLens?
OncoLens operates as a sophisticated digital healthcare platform designed to streamline the complexities of oncology workflows. By integrating multidisciplinary care solutions, the platform serves a vast network of over 5 million patients and 45,000 physicians. Its market penetration is notable, with adoption across 10% of U.S. cancer centers and 50% of top-tier pharmaceutical companies. The platform's core value proposition lies in its ability to enhance patient outcomes through precision biomarker testing, optimized trial matching, and coordinated clinical decision support, effectively bridging the gap between healthcare providers and life sciences organizations.
How much funding has OncoLens raised?
OncoLens has raised a total of $27.1M across 4 funding rounds:
Angel/Seed
$1.4M
Private Equity
$2.5M
Series A
$7.3M
Series B
$16M
Angel/Seed (2019): $1.4M, investors not publicly disclosed
Private Equity (2020): $2.5M led by BIP Capital, Robbins Fund, and Atlanta Technology Angels
Series A (2021): $7.3M supported by Martin Ventures and BIP Capital
Series B (2024): $16M featuring Martin Ventures, BIP Capital, SeedtoB Capital, and Cross-Border Impact Ventures
Key Investors in OncoLens
Martin Ventures
Martin Ventures is a firm that invests in innovative healthcare companies, focusing on transforming the healthcare ecosystem to reward providers for achieving excellent health outcomes.
BIP Capital
BIP Capital is a vertically-integrated investment firm that specializes in private equity and credit investment strategies aimed at supporting wealth advisors and their clients.
SeedtoB Capital
SeedtoB Capital is an investment firm focused on supporting healthcare AI startups, particularly those in the Seed and Series A stages, to navigate their path to Series B funding.
What's next for OncoLens?
With this major enterprise-level funding, OncoLens is positioned to accelerate its expansion into new clinical segments and deepen its technological moat. The strategic focus will likely center on scaling its AI-enabled diagnostic capabilities and expanding its footprint within the pharmaceutical research sector. As the company transitions from its growth phase into a more mature enterprise lifecycle, the focus will remain on maintaining its high-velocity adoption rate while navigating the evolving landscape of value-based cancer care. The continued support from its core investor base underscores confidence in the platform's ability to drive systemic improvements in oncology outcomes.
See full OncoLens company page
